A prospective, multicenter, double-blind, randomized controlled clinical study evaluating the efficacy and safety of all-trans retinoic acid combined with decitabine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (MDS) with high RARA expression

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 8ce5226a2cb942e65068763ee26d0ba49796a879
First added on: May 09, 2026